Higher FEZF1-AS1 expression is linked to clinicopathological factors, such as lymph node metastasis, higher pathologic T stage, invasion, and distant metastasis, leading to lower survival rates in individuals with these tumors. Here, FEZF1 is linked to metastatic malignant neoplasm in the lymph nodes.